LTR PHARMA FPO (ASX: LTP) — Perfil da empresa, notícias e dados financeiros
LTR PHARMA FPO is a clinical-stage biopharmaceutical company focused on improving men's health through the development and commercialisation of fast-acting delivery platforms.
LTR PHARMA FPO
LTR PHARMA FPO is a clinical-stage biopharmaceutical company focused on improving men's health through the development and commercialisation of fast-acting delivery platforms. The company's lead product candidate, SPONTAN, is a novel intranasal spray formulation of a phosphodiesterase-5 inhibitor designed for the rapid on-demand treatment of erectile dysfunction. Beyond its core intranasal delivery technology, the business expands its men's health portfolio through distribution and commercialisation agreements for approved treatments, including oral testosterone replacement therapies. Based in Australia, the company conducts clinical development, regulatory filings, and commercial partnerships to disrupt traditional oral tablet markets.
Resumo
Operações
Produtos e/ou serviços de LTR PHARMA FPO
- Erectile Dysfunction Therapeutics: Intranasal vardenafil delivery platform engineered for rapid absorption and onset of action within ten minutes, providing on-demand treatment for erectile dysfunction with reduced systemic exposure compared to oral PDE5 inhibitor tablets.
- Testosterone Replacement Therapies: Commercialisation and distribution of FDA-approved oral testosterone undecanoate capsules in Australia, offering targeted treatment options for men suffering from testosterone deficiency, low energy, and related metabolic conditions.
- Special Access Scheme Access: Early patient access program supplying nasal spray formulations directly to qualified healthcare practitioners and eligible patients across Australia under Therapeutic Goods Administration regulatory frameworks prior to full market authorization.
- Clinical Study Programs: Execution of Phase II pharmacokinetic trials and bioequivalence datasets to support streamlined regulatory submissions, including United States Food and Drug Administration Section 505(b)(2) New Drug Application approval pathways.
equipe executiva do LTR PHARMA FPO
- Lee RodneExecutive Chairman
- Jacques SchipperChief Financial Officer
- Peter McLennanChief Operating Officer
- Geoffrey A. StrangeChief Medical Officer
- Danny ZanardoChief Commercial Officer
- Euh HwangJoint Company Secretary
- Elizabeth SpoonerJoint Company Secretary
Últimas notícias sobre a LTR PHARMA FPO
LTR Pharma completes key study achieving sixfold faster absorption
AustraliaLTR Pharma books $19.7M cash reserves, zero debt in FY26
AustraliaLTR Pharma signs deal to deliver 150,000 ROXUS units
AustraliaLTR Pharma secures US telehealth deal for ROXUS
AustraliaLTR Pharma completes recruitment for SPONTAN Phase 2 study
AustraliaLTR Pharma begins Phase 2 trial of SPONTAN for ED
Australia
Comunicados recentes
O que a LTR PHARMA FPO (LTP) comunicou ao mercado, do mais recente para o mais antigo.
- Investor Webinar Presentation
- First ROXUS Prescriptions Fulfilled in the United StatesFato relevante
- Clinical and Commercial Update - Investor Webinar
- SPONTAN Phase II Final ResultsFato relevante
Principais indicadores financeiros
Resultados divulgados pela LTR PHARMA FPO, em AUD.
- Cap. de mercado
- 78,7 mi
- Receita (TTM)
- 723,9 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 183,9 mil | -14,5 mi | -14,2 mi | |
| 2,1 mi | -5,2 mi | -5,6 mi | |
| 49,3 mil | -6,4 mi | -7 mi | |
| 90 | -1,4 mi | -1,5 mi |